Xin Lang Cai Jing·2025-12-19 08:17Group 1 - The core announcement is the appointment of Wang Lai as the new President and Global Head of R&D at BeiGene, effective December 18 [1][3] - Wang Lai has been with BeiGene since 2011 and has held various leadership roles in R&D, previously serving as the Research Director at Joyant Pharmaceuticals from 2008 to 2011 [1][3] - The previous President, Wu Xiaobin, will retain all his positions and responsibilities, leading to a "dual presidency" at the company [3][5] Group 2 - Wu Xiaobin has over 25 years of experience in the pharmaceutical industry and has worked with major companies like Bayer, Wyeth, and Pfizer [5][15] - BeiGene is the first biotech company to be listed on NASDAQ, Hong Kong Stock Exchange, and Shanghai Stock Exchange, with two major products: the BTK inhibitor Zanubrutinib and the PD-1 inhibitor Tislelizumab [5][15] - Zanubrutinib achieved global sales of $1.3 billion in 2023, marking it as the first domestic drug to exceed the billion-dollar sales threshold [5][15] Group 3 - BeiGene is the only innovative pharmaceutical company with two drugs included in commercial insurance: Zhenida Monoclonal Antibody and Dato-DXd [6][16] - For the first three quarters of 2025, BeiGene reported revenue of 27.595 billion yuan, a year-on-year increase of 44.2%, and a net profit of 1.139 billion yuan, successfully turning a profit [6][16] - The company raised its revenue guidance for the full year of 2025 to between 36.2 billion and 38.1 billion yuan, up from the previous estimate of 35.8 billion to 38.1 billion yuan [7][17] Group 4 - On December 19, BeiGene's A-shares rose by 0.86%, closing at 274 yuan per share, with a total market capitalization of 422.1 billion yuan [8][18]